medigraphic.com
Academia Mexicana de Neurología, A.C.

2008, Number 3

<< Back Next >>

Rev Mex Neuroci 2008; 9 (3)

Anxiety disorders and co-morbid of the consumption of psychotropic and other substances of abuse

Souza MM

Language: Spanish
References: 72
Page: 215-226
PDF size: 90.26 Kb.


ABSTRACT

Anxiety disorders, characterized by behavioral and physiological changes similar to those caused by fear, show symptomatic similarity unclear for the patient, making difficult its diagnosis and treatment. Its various clinical conditions are associated to addiction in its dual nature: of psychiatric and addictive co-morbidity (derived from psychotropic consumption or other abuse/dependence substances). Its etiology has available for its study, several theoretical points of view (psychodynamic, behavioral, and cognitive). Beyond the terminological confusion between anxiety, anguish, and panic attack, anxiety is distinguished between exogenous (phobias) and endogenous anxiety (panic and generalized anxiety). Its clinical variations: generalized anxiety disorder, panic attack; fobic disorders (specific phobias, social phobia and agoraphobia without panic disorder) PTSD; obsessive-compulsive disorder; anxiety disorder, due to medical condition induced by drugs require for their diagnosis the analysis of the deployment and evolution of symptoms and family history. Primary care personnel in the various countries take care of 90% of the cases. However, they only derive to a specialist (psychiatrist, neurologist, etc.) those cases with psychotic signs, suicidal attempts, episodes associated with bipolar disorder, or because of lack of response to treatment. This should promote reconsideration of their professional performance, not only at their basic training but also at the continuous one, in main psychiatric issues such as anxiety and co-morbidity, key ones for early detection, improved diagnosis and proper treatment.


REFERENCES

  1. Sadock BJ, Sadock VA. Kaplan and Sadock’s Synopsis of Psychiatry. 10th Ed. Lippincott Williams & Wilkins; 2007.

  2. Lauderdale SA, Javaid I. Sheikh. Anxiety disorders in older adults. Clinics in Geriatric Medicine Clin Geriatr Med 2003; 19(4): 721-41.

  3. Babcock RL, Laguna LB, Laguna KD, Urusky DA. Age differences in the experience of worry. J Mental Health Aging 2000; 6: 227-35.

  4. Souza y MM. Educación, salud y adicciones. Rev Mex Neuroci 2003; 4(2): 91-3.

  5. Guisa CVM, Díaz Barriga SL, Souza y MM. Terapéutica antiadictiva. Utilidad de sus factores de predicción. Rev Mex Neuroci 2004; 5(6): 581-98.

  6. De Beurs E, Beekman ATF, van Balkom AJL, Deeg DJH, van Dyck R, van Tilburg W. Consequences of anxiety in older persons: its effect on disability, well-being, and use of health services. Psychol Med 1999; 29: 583-93.

  7. Debeurs E, Beekman ATF, Deeg DJH. Predictors of change in anxiety symptoms of older persons: Results from the longitudinal aging study Amsterdam. Psychol Med 2000; 30: 515-27.

  8. Paris J. Anxious traits, anxious attachment, and anxious-cluster personality disorders. Harvard Rev Psychiatry 1998; 6: 142-8.

  9. Souza y MM. El papel de la mitología popular, la semántica y la iatrogenia en las adicciones. Rev Mex Neuroci 2002; 2(1): 25-7.

  10. Fava M, Rankin MA, Wright EC. Anxiety disorders in major depression. Compr Psychiatry 2000; 41: 97-102.

  11. Lenze EJ, Mulsant BH, Shear MK, Schulberg HC, Dew MA. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry 2000; 157: 722-8.

  12. Souza y MM. Por una psiquiatría de las adicciones. Rev Mex Neuroci 2003; 4(4): 206-8.

  13. Roy-Byrne PP, Katon W. Anxiety management in the medical setting: rationale, barriers to diagnosis and treatment, and proposed solutions. In: Mostofsky DI, Sartorius N, Ustun T, Lecrubier Y, Wittchen H (eds.). Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry 1996; 168: 38-43.

  14. Saviñón TJA, Solis MR, Johnson RR. Trastornos por Pánico: Aspectos Clínicos y Psicofarmacológicos. Rev Neurología Neurocirugía y Psiquiatría 2002; 35(1): 97-106.

  15. Sheehan DV. Panic attacks and phobias. NEJM 1982; 307: 156-8.

  16. Tracey SA, Chorpita BF, Douban J. Empirical evaluation of DSM-IV generalized anxiety disorder criteria in children and adolescents. J Clin Child Psychiatry 1997; 26: 404-14.

  17. Otto MW, Tuby KS, Gould RA, Mclean RYS, Pollack MH. An effect size-analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001; 158: 1989-92.

  18. Rickels K, Schweizer EE. Current pharmacotherapy of anxiety and panic. In: Meltzer HA (ed.). Psychopharmacology: the third generation of progress New York: Raven Press; 1987, p. 1193-203.

  19. Roy-Byrne PP, Katon W, Cowley DS, Russo J. A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care. Arch Gen Psychiatry 2001; 58: 869-76.

  20. Swales PJ, Solfvin JF, Sheikh JI. Cognitive-behavioral therapy in older panic disorder patients. Am J Geriatr Psychiatry 1996; 4: 46-60.

  21. Mohlman J, Gorenstein EE, Kleber M, De Jesus M, German JM, Papp L. Standard and enhanced cognitive-behavioral therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry 2003; 11: 24-32.

  22. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50: 85-94.

  23. Souza y MM. Personalidad y adicciones. Rev Mex Neuroci 2005; 6(4): 336-45.

  24. Rickels K, Rynn M. Overview and Clinical Presentation of Generalized Anxiety Disorder. Psychiatric Clinics of North America 2001; 24(1): 123-32.

  25. World Health Organization, WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: WHO; 1993.

  26. American Psychiatric Association, APA. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, text revision, Washington, DC: American Psychiatric Association; 2000.

  27. Cassano GB, Michelini S, Shear MK. The panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms. Am J Psychiatry 1997; 154: 27-38.

  28. Akiskal HS. Toward a definition of generalized anxiety disorder as an anxious temperament type. Acta Psychiatr Scand 1998; 98(Suppl. 393): 66-73.

  29. Rickels K, Rynn M. Overview and Clinical Presentation of Generalized Anxiety Disorder. Psychiatric Clinics of North America 2001; 24(1): 123-32.

  30. Torgersen S. Genetic factors in anxiety disorders. Arch Gen Psychiatry 1983; 40: 1085-9.

  31. Sussman N. Toward an understanding of the symptomology and treatment of generalized anxiety disorder. Prim Psychiatry 1997; 4: 68-81.

  32. Souza y MM, Guisa CVM, Díaz Barriga SL. TDAH y su comorbilidad adictiva. Rev Mex Neuroci 2005; 6(3): 227-44.

  33. Souza y MM. Consideraciones y fundamentos para una terapéutica profesional de las adicciones. Psiquiatría 2003; 19(3): 16-9.

  34. Souza y MM. Diagnóstico y tratamiento de los síndromes adictivos. México: Ciencia y cultura Latinoamérica; 2000.

  35. Souza y MM. Programa profesional terapéutico contra las adicciones. Una propuesta integrativa. Psiquiatría 2005; 21(1): 25-37.

  36. Souza y MM. Adicciones, psicopatología y psicoterapia. Rev Mex Neuroci 2004; 5(1): 57-69.

  37. Barlow DH (ed.). The management of stress and anxiety in medical disorders. Boston: Allyn and Bacon; 2000, p. 1-14.

  38. Barlow DH, Lehman CL. Advances in the psychosocial treatment of anxiety disorders: implications for national health care. Arch Gen Psychiatry 1996; 53: 727-35.

  39. Alarcón RD. Trastorno de estrés post-traumático: Revisión de la literatura. Rev Neuro-Psiquiatría 1994; 57: 6-20.

  40. Pollack MH, Zainelli R, Goddard A, Mccafferty JP, Bellew KM, Bumham DB. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible dosage trial. J Clin Psychiatry 2001; 62: 350-7.

  41. Beck JG, Stanley MA. Anxiety disorders in the elderly: the emerging role of behavior therapy. Behav Ther 1997; 28: 83-100.

  42. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. NEJM 1993; 328: 1398-404.

  43. Smiley A, Moskowitz H. Effects of long-term administration of buspirone and diazepam on driver steering control. Am J Med 1986; 80: 22-9.

  44. Rickels K, Schweizer EE, Csanalosi I, Case WG, Chung H. Longterm treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45: 444-50.

  45. Rickels K, Downing R, Schweizer E. Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884-95.

  46. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JRT. Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. Br J Psychiatry 1999; 175: 17-22.

  47. Jenike MA, Baer L, Minichiello WE, Rausch SL, Buttolph ML. Placebocontrolled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997; 154: 1261-4.

  48. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Dominguez RA. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51: 559-67.

  49. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 45-9.

  50. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder: twenty-four week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15-22.

  51. Alpert JE, Uebelacker LA, Mclean NE. Social phobia, avoidant personality disorder, and atypical depression: co-occurrence and clinical implications. Psychol Med 1997; 27: 627-33.

  52. Regier DA, Farmer ME, Rae DS. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiological catchment area (ECA) study. JAMA 1990; 264: 2511-8.

  53. Foa EB, Gilboa-Schechtman E, Amir N. Memory bias in generalized social phobia: remembering negative emotional expressions. J Anxiety Disord 2000; 14: 501-19.

  54. Stein MB, Torgrud LJ, Walker JR. Social phobia symptoms, subtypes, and severity. Arch Gen Psychiatry 2000; 57: 1046-52.

  55. Tagle OI, Mercado CG, Martínez AJ, Martínez MJ, Souza y MM. ¿Por qué profesionalizar la terapéutica de las adicciones? Psiquiatría 2000; 16(3): 110-6.

  56. Goddart NT, Flament MF, Lecrubier Y. Anxiety disorders in anorexia nervosa and bulimia nervosa: co-morbidity and chronology of appearance. Eur Psychiatry 2000; 15: 38-45.

  57. Averill PM, Beck JG. Posttraumatic stress disorder in older adults. J Anxiety Disord 2000; 14: 133-56.

  58. Simpson HB, Schneier FR, Campeas R. Imipramine in the treatment of social phobia. J Clin Psychopharmacol 1998; 18: 132-5.

  59. Souza y MM. Alcoholismo: conceptos básicos. México: Ed. El Manual Moderno; 1985.

  60. Souza y MM. Adicciones Clínica y Terapéutica. México: Editorial Alfil; 2007.

  61. Souza y MM. Repercusiones psiquiátricas y psicosociales en las víctimas de desastres: el caso Tsunami. México: Comisión de Marina. Senado de la República; 2005.

  62. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes C. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283: 1837-44.

  63. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996; 169: 468-74.

  64. Davis LL, Nugent AL, Murray J, Kramer GL, Petty F. Nefazodone treatment for chronic posttraumatic stress disorder: an open trial. J Clin Psychopharmacol 2000; 20: 159-64.

  65. Conner KM, Davidson JRT, Weisler RH. A pilot study of mirtazapine in posttraumatic stress disorder. In: Scientific abstracts of the 37th Annual Meeting of the American College of Neuropsychopharmacology; December 14-18, 1998; Las Croabas, Puerto Rico.

  66. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebocontrolled study. Am J Psychiatry 2001; 158: 1982-8.

  67. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D. Efficacy of sertraline, in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 2002; 159: 88-95.

  68. Wetherell JL, Arean PA. Psychometric evaluation of the Beck Anxiety Inventory with medical patients. Psychol Assess 1997; 9: 136-44.

  69. Souza y MM. Nosología y propedéutica de los programas antiadictivos. Rev Mex Neuroci 2005; 6(2): 166-179.

  70. Mcdougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH. The efficacy of fluvoxamine in obsessive compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 1993; 13: 354-8.

  71. Souza y MM, Cruz MDL. Bebidas “energizantes”, educación social y salud. Rev Mex Neuroci 2007; 8(2): 189-204.

  72. Guisa CVM, Díaz Barriga SL, Souza y MM. La educación médica en adicciones y sus problemas. Psiquiatría 2004; 20(1): 9-20




2020     |     www.medigraphic.com